Kornimate/medical-research-clean huggingface dataset:
labor scale versus who partograph in the management of labor

Conditions: Dystocia

Summary: this study aims to compare the novel labour scale with the traditional who partograph in the management of spontaneous labour in primigravida in terms of maternal and neonatal outcomes

after many centuries through which vaginal delivery (vd) had been the only safe route of birth, cesarean section (cs) emerged as an alternative in emergency situations. cs has gradually become an appealing option for both the mother and the obstetrician and its indications increase while cs was proving safety; the rate of cs in u.s.a increased by about 50% within 10 years around the beginning of the current century. however, the increasing prevalence of cs raises questions about the impact of this trend on maternal morbidity, mortality as well as its economic burden. accordingly, recent guidelines have been directed to revise practice-base cs indications to only situations when cs is truly beneficial to the mother and/or the fetus. of these indications, the most reported one was labour dystocia. the who partograph is a famous chart that is commonly used to observe uncomplicated labour and is almost an objective approach to guide interference. unfortunately, the rule of the partograph in reducing the incidence of cs is questionable. furthermore, the design of the partograph is not exactly perfect to present the process of labour. for these reasons, the labour scale was designed as a novel follow-up chart during labour. the chart considered more objective and timed management of labour with more flexible range of time based on recent evidence. a previous pilot study on 77 women suggested that the labour scale may be a good alternative to the current partograph. this study is the first randomized trial the compares the 2 charts as regards the rate of cs, maternal and neonatal health outcomes and both patient and obstetrician satisfaction. in this clinical trial, the investigators aim to compare the labour scale to the traditional who partograph in terms of incidence of labor dystocia and cs as well as maternal and neonatal outcomes

Eligibility criteria:
inclusion criteria: * primigravida * 38 - 42 weeks of gestation * singleton pregnancy * vertex presentation * spontaneous labour * average estimated fetal weight (2500 - 3800 gram) exclusion criteria: * maternal medical or surgical major co-morbidity * previous uterine scar * induction of labor * premature rupture of membranes

Keywords: labor scale partograph spontaneous labor primigravida
advancing stroke safety and efficacy through early tirofiban administration after intravenous thrombolysis (asset-it)

Conditions: Acute Ischemic Stroke

Summary: to assess the efficacy and safety of tirofiban administration after intravenous thrombolysis for patients with ais.

the standard treatment for acute ischemic stroke is intravenous thrombolysis to dissolve fibrin and restore blood flow. however, reocclusion of blood vessels and stroke progression remain challenges after this treatment.

Eligibility criteria:
inclusion criteria: 1. onset of ischemic stroke symptoms within ≤ 4.5 hours\*, treated with intravenous rt-pa or tnk according to guidelines; 2. nihss score of 4-25 before intravenous thrombolysis; 3. age ≥ 18 years; 4. able to receive the designated study drug within 60 minutes after intravenous thrombolysis; 5. informed consent signed by the patient or their legal representative. \*symptom onset is defined as the last known well time. exclusion criteria: 1. presence of contraindications to intravenous thrombolysis; 2. pre-stroke mrs score \> 1; 3. patients planned to undergo mechanical thrombectomy or other endovascular treatments (e.g., intra-arterial thrombolysis); 4. patients with a history of atrial fibrillation or emergency ecg indicating atrial fibrillation; 5. pregnant or lactating women; 6. ncct, cta source imaging, or mri-dwi showing aspects or pc-aspects \< 6; 7. if nihss worsens by 2 or more points between start of thrombolysis and start of study drug, repeat brain imaging rules out new intracranial hemorrhage; 8. severe leukoaraiosis; 9. currently participating in other clinical trials; 10. known genetic or acquired bleeding diathesis, or received warfarin and inr \> 1.7; or treated with direct oral anticoagulant agents in the prior 48 hours; 11. severe renal failure, defined as serum creatinine \> 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate \[gfr\] \< 30, or patients requiring hemodialysis or peritoneal dialysis; 12. liver dysfunction (alt \> 2 times the upper limit of normal or ast \> 2 times the upper limit of normal); 13. known allergy to tirofiban or other iib/iiia inhibitors; 14. life expectancy \< 1 year; 15. inability to complete 90-day follow-up (e.g., no fixed residence, overseas patients, etc.).

Keywords: tirofiban intravenous thrombolysis
radicular cyst enucleation using piezosurgery versus conventional surgery

Conditions: RADICULAR CYSTS

Summary: aim: the study was intended to evaluate the effectiveness of piezosurgery in enucleation of radicular odontogenic cysts in comparison to the conventional technique from both the clinical and radiographic perspectives.

methods: fourteen (8 females and 6 males) patients with age range of 30-55 years who had radicular cysts associated with non-vital teeth, were operated at the oral and maxillofacial surgery department, faculty of dentistry, alexandria university. the patients were randomly divided into 2 groups;1) the study group (7 patients) in which cyst enucleation using piezosurgery was employed, 2) control group in which the cysts were removed using the conventional technique. the following parameters were assessed; postoperative pain, time of operation, hemorrhage control and field visibility, ease of operation, neurosensory evaluation and radiographic percentage of change in bone defect volume between preoperative and 3-months postoperative values.

Eligibility criteria:
inclusion criteria: * 1) periapical cysts involving more than one tooth in close relation to the maxillary sinus, nasal cavity or inferior alveolar neurovascular bundle, * 2) intact labial/buccal cortical plate with no perforation. exclusion criteria: * 1) patients with systemic diseases contraindicating surgery * 2) cases in suspicion of malignancy
the impact of esmolol administration on postoperative recovery

Conditions: Pain, Acute; Pain, Postoperative; Pain, Chronic Post-Surgical; Esmolol; Inguinal Hernia Repair; Analgesia; Nociceptive Pain

Summary: the aim of this study will be to investigate the effect of a continuous infusion of low dose esmolol on intraoperative and postoperative opioid consumption, as well as on postoperative recovery and chronic pain

contemporary anaesthesiology requires the quest of ways to restrict the use of opioids, which aim at the alleviation of severe postoperative and chronic pain. this is not only due to the side effects involved but also to the epidemic dimensions their use entails. esmolol, an extremely short-acting cardioselective antagonist of β1 adrenergic receptors, is effectively used in order to attenuate the stress response and minimize undesirable perioperative hemodynamic changes. more specifically, esmolol has been used effectively to reduce pain during induction of anesthesia with propofol and treat tachycardia and hypertension during laryngoscopy. however, recent studies also highlight a possible antinociceptive and/or analgesic effect of esmolol. therefore, the aim of this study will be to investigate the effect of a continuous infusion of low dose esmolol on intraoperative and postoperative opioid consumption, as well as on postoperative recovery and chronic pain

Eligibility criteria:
inclusion criteria: * adult patients * american society of anesthesiologists (asa) classification i-ii * elective inguinal hernia repair exclusion criteria: * body mass index (bmi) \>35 kg/m2 * β-blocker administration preoperatively * systematic use of analgesic agents preoperatively * chronic pain syndromes preoperatively * neurological or psychiatric disease on treatment * pregnancy * severe hepatic or renal disease * history of cardiovascular diseases/ arrhythmias/ conduction abnormalities * hemodynamic instability * drug or alcohol abuse * language or communication barriers * lack of informed consent * bilateral inguinal hernia repair
early mechanical ventilation for guillain barré syndrome

Conditions: Guillain Barré Syndrome; Acute Respiratory Failure

Summary: the purpose of this study is to determine whether early mechanical ventilation can prevent hospital acquired pneumonia in adults with guillain barré syndrome.

hospital acquired pneumonia is a common and severe complication of guillain barré syndrome. several factors have been recognized as predictors of respiratory failure in adults with guillain barré syndrome. they include a time from disease onset and patient admission of less seven days, inability to lift head, impaired swallowing and a forced vital capacity of less than 60% of predictive value. we reasonned that early mechanical ventilation may prevent aspiration which is likely the main cause of pneumonia in these patients.

Eligibility criteria:
inclusion criteria: * guillain barré syndrome * age of 18 years old or more * inability to lift head * time from onset of motor deficit less than 7 days * written informed consent exclusion criteria: * glasgow coma score of less than 8 * unstable hemodynamic status * current pneumonia * pregnancy

Keywords: guillain barré mechanical ventilation, invasive mechanical ventilation, non invasive pneumonia
tear analysis in the diagnosis of multiple sclerosis

Conditions: Primary Progressive Multiple Sclerosis

Summary: in the primary progressive multiple sclerosis, the detection of oligoclonal bands in cerebrospinal fluid is critical for the diagnosis. however, lumbar puncture for cerebrospinal fluid collection is considered relatively invasive. our hypothesis is that oligoclonal bands detection in tears is possible and useful for the diagnosis of multiple sclerosis.

the objective of the present study is to assess concordance between oligoclonal bands detection in tears and in cerebrospinal fluid. we will include patients with primary progressive multiple sclerosis and we will compare results of oligoclonal bands detection by isoelectric focusing in cerebrospinal fluid and tears. tears will be collected using a schirmer strip. this would circumvent the practice of invasive lumbar punctures currently used in multiple sclerosis diagnosis.

Eligibility criteria:
inclusion criteria: * 18 years old or more * progressive neurological deficit after 12 months * at least 9 t2 brain lesions of minimum 3 mm evidenced by mri and/or four or more t2 lesions of minimum 3 mm with positive visual evoked potential and/or positive spinal cord mri (at least two focal t2 lesions) exclusion criteria: * asiatic persons * recurrent forms of the disease * persons wearing contact lenses * ocular infection * corticoid treatment at least 30 days before sampling * immunosuppressive or immunomodulatory treatment 3 months before sampling

Keywords: primary progressive multiple sclerosis diagnosis tears isoelectric focusing oligoclonal bands
oncofish cervical test for detection of 3q26 region gain

Conditions: Cervical Cancer; LSIL

Summary: the purpose of this study is to evaluate the use of the oncofish cervical test system in the management of women who have received an lsil pap report to determine whether the test can predict which women will progress to more serious cervical disease and which women do not have to be monitored as closely.


Eligibility criteria:
inclusion criteria: * women 21 years of age or greater with recent lsil who are scheduled for colposcipal assessment. * women with previous or current std or hiv may be included * women with previous lsil history may be included. exclusion criteria: * pregnant women, * women with vaginal intraepithelial lesions, * women on a chemotherapeutic agent, * women with previous or current cancer except for non-cervical squamous cell carcinoma
mage-a4ᶜ¹º³²t for multi-tumor

Conditions: Urinary Bladder Cancer; Melanoma; Head and Neck Cancer; Ovarian Cancer; Non-Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Synovial Sarcoma; Myxoid Round Cell Liposarcoma; Gastroesophageal Junction

Summary: this study will investigate the safety and tolerability of mage-a4ᶜ¹º³²t cell therapy in subjects who have the appropriate hla-a2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (mrcls) tumor has the mage-a4 protein expressed. this study will take a subject's t cells and give them a t cell receptor protein that recognizes and attacks the tumors. this study has a substudy component that will investigate the safety and tolerability of mage-a4c1032t cell therapy in combination with low dose radiation in up to 10 subjects.


Eligibility criteria:
inclusion criteria: 1. subject is ≥18 to 75 years of age at the time of signing the study informed consent. 2. subject has histologically confirmed diagnosis of any one of the indicated tumor types 3. subject is hla-a\*02 positive. (this determination will be made under screening protocol adp-0000-001). 4. subject's tumor shows expression of the mage-a4 rna or protein. (this determination will be made under screening protocol adp-0000-001). 5. adequate organ function as indicated in the study protocol 6. subject has measurable disease according to recist v1.1 criteria prior to lymphodepletion 7. subject meets disease-specific requirements per protocol 7. subject has anticipated life expectancy \> 6 months prior to leukapheresis and \>3 months prior to lymphodepletion. exclusion criteria: 1. subject does not express appropriate hla-a genotype 2. subject is receiving excluded therapy/treatment per protocol 3. subject has symptomatic cns metastases. 4. subject has any other active malignancy besides the tumor under study within 3 years prior to screening. subject has uncontrolled intercurrent illness. 5. subject has active infection with hiv, hbv, hcv or htlv 6. subject is pregnant or breastfeeding. additional exclusion criteria for the radiation substudy: * subject does not meet eligibility criteria for the main study (adp-0044-001). * subject does not have at least one target lesion amenable to radiation. * certain radiation therapy within 6 months of clinical trial are an exclusion. * metastatic disease impinging on the spinal cord or threatening spinal cord compression.

Keywords: cell therapy t cell therapy spear t cell mage-a4 immuno-oncology metastatic urothelial cancer previously treated t cell receptor squamous, adenosquamous, adenocarcinoma or large cell nsclc squamous or adenocarcinoma esophageal cancer sarcoma melanoma bladder ovarian radiation therapy
evaluation of the treatment of multiple gingival recession using modified coronally advanced tunnel with subepithelial connective tissue graft depending on the positioning of the graft

Conditions: Gingival Recession

Summary: microsurgical coronally advanced tunnel procedures using subepithelial connective tissue grafts (sctg) are predictable for healing of multiple adjacent type 1 and 2 gingival recessions (rt1 and rt2). in order to reduce patient morbidity and enhance periodontal wound healing with sctg can be used. the aim of this study is to compare the results of the modified tunneling technique with subepithelial connective tissue graft in gingival recessions placed with the inner side towards the flap cover graft and the outer side towards the flap cover graft.

condition or disease:multiple gingival recession intervention/treatment: device: modified coronally advanced tunnel with connective tissue graft placed with inner side towards the flap device: modified coronally advanced tunnel with subepithelial connective tissue graft with the outer side towards the flap phase :not applicable

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * bilateral multiple gingival recessions in homologous teeth in the same arch. exclusion criteria: * full-mouth plaque index ≥ 20% (ainamo \& bay 1975) * full-mouth sulcus bleeding index ≥ 15% (mühlemann \& son 1971) * smoking * systemic diseases with compromised healing potential of infectious diseases * drugs affecting periodontal health / healing * pregnant and lactating females * previous periodontal surgery in the area

Keywords: tunneling technique
observing the relationship of fibroblast growth factor and fibroblast in thyroid eye disease

Conditions: Graves Ophthalmopathy

Summary: graves' orbitopathy (go) affects about 50% of patients with graves' disease (gd), and some cannot be cured by current treatments. orbital fibroblasts involves in the pathogenesis of go by producing glycosaminoglycans and inflammatory cytokines. since fibroblast growth factors (fgfs) binding to fgf receptors (fgfrs) can induce proliferation and differentiation of fibroblasts, investigators would like to measure the expression of fgfs and fgfrs in go patients to see if inhibition of fgf-fgfr pathway has potential in treatment.


Eligibility criteria:
inclusion criteria: * diagnosed as thyroid eye disease * suggested to accept orbital decompression exclusion criteria: * age below 20 or above 80 * pregnancy

Keywords: fibroblast growth factors fibroblast growth factors receptors thyroid orbitopathy
patient-reported monitoring of symptoms and spirometry via the patientmpower platform in idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary fibrosis (ipf) over 16 weeks. patients will use an electronic health journal (patientmpower platform) to record treatment compliance, forced vital capacity (fvc; daily), impact of ipf on daily life (weekly) and other symptoms. objectives are to characterise acceptability of patientmpower platform from patient \& healthcare professional perspective, impact of active engagement and self-monitoring using patientmpower platform on patient reported outcome measures (proms) in ipf, impact of patientmpower platform on medication compliance and correlation between patient-reported proms \& fvc and clinical outcomes.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of idiopathic pulmonary fibrosis (ipf). * daily unrestricted access to smartphone or tablet device at home. * demonstrated understanding of protocol and correct use of spirobank smart spirometer and patientmpower platform. * able and willing to perform spirometry every day at home. * willing to give written informed consent exclusion criteria: * significant confusion or any concomitant medical condition which would limit the ability of the patient to record symptoms or use a home spirometer on a regular basis. * new prescription of antifibrotic therapy for ipf (e.g. pirfenidone, nintedanib) within 4 weeks before baseline visit. * recent exacerbation of ipf or other clinically significant change in the patient's medical condition in 4 weeks before baseline visit

Keywords: digital health home spirometry patient reported outcome measure e-health pirfenidone nintedanib fvc antifibrotic
the comparison of rcd versus bcd in newly diagnosed waldenström macroglobulinemia

Conditions: Waldenström Macroglobulinemia

Summary: the purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone combined with rituximab or bortezomib regimens in newly diagnosed waldenström macroglobulinemia patients.

newly diagnosed wm patients will be randomly assigned to bcd or rcd group for introduction chemotherapy. chemotherapeutic response will be evaluated after 3 cycles. if a pr or better response achieves, addition 3 cycles will be given. if not, patients will be crossed to control group for another 3 cycles. if a pr or better response comes out, addition 3 cycles will be given, otherwise, the patients will quit this study.

Eligibility criteria:
inclusion criteria: 1. aged \>=18 years 2. diagnosed with lpl/wm 3. untreated or mild treated without standard regimens,especially untreated with rituximab and/or bortezomib 4. symptom patients 5. with life-expectancy more than 3 months. exclusion criteria: 1. diagnosed with other malignancies outside b-nhl within one year(including active center neural system lymphoma) 2. transformed lymphoma 3. liver or renal function lesion unrelated to lymphoma 4. serious complications such as uncontrolled diabetes,gastric ulcer or other serious angiocardiopathy determined by the physician 5. hiv positive or active hbv infection or other uncontrolled systematic infection 6. clinical central nervous dysfunction 7. serious surgery within 30 days 8. pregnancy or baby nursing period or un-contracepted child-bearing period woman; 9. allergy to the trail drugs.
effects of trans-resveratrol in endothelial function in hypertensive patients

Conditions: Endothelial Dysfunction

Summary: arterial hypertension (hbp) has a high prevalence and low rates of control, is considered a major modifiable risk factors and one of the most important public health problems. mortality from cardiovascular disease increases progressively with increasing blood pressure (bp) in a linear, continuous and independent. the pathophysiological mechanisms involved in the pathogenesis of hypertension exhibit metabolic abnormalities, which are related to endothelial dysfunction. resveratrol, a polyphenol stilbene derived from various species of plants, but in our food, mainly present in red wine and grapes, has shown protective effects in cardiovascular diseases, such as preventing the damage caused by oxidative stress, decreased plasma lipids with inhibiting the formation of atherosclerotic plaque; protective effect of vascular endothelium, with increased release of nitric oxide and decreased production of free radicals in animal models, but human studies are limited and insufficient to clarify the possible effects of trans-resveratrol (biologically active form) on endothelial function, blood pressure and central aortic pressure in treated hypertensive individuals.the aim of this study is to evaluate the acute effects of trans-resveratrol supplementation on endothelial function in treated hypertensive patients.


Eligibility criteria:
inclusion criteria: * outpatients aged between 45 and 65 years, of both genders. * patients with a previous diagnosis of hypertension. * patients with endothelial disfunction. * stable use of antihypertensive treatment for at least 2 months. * patients with food consumption maintained for at least 4 weeks, oriented to limit the intake of foods rich in polyphenols, such as peanut butter, cranberry, blackberry, red grapes, red wine, green tea and chocolate. * signing the consent form. exclusion criteria: * smoking. * diabetes mellitus and / or use of insulin or oral hypoglycemic agents. * hormone replacement therapy. * use of ß-blockers and statins. * sleep apnea. * changes in thyroid function, chronic renal and liver diseases. * clinically evident coronary heart disease with previous myocardial infarction and / or revascularization, with clinical signs of heart failure, cardiac arrhythmia, symptomatic or clinically significant valvular disease, prior stroke. * history of drug or alcohol abuse. presence of some kind of eating disorder; * diets restricted by choice (vegetarianism, carbohydrate restriction); * use of nutritional supplements (vitamins, minerals), to at least seven (7) days prior to the study; * patients who have any severe illness and life-threatening any condition, disease or therapy that, in the opinion of the investigator, may adversely affect the results, interfere with the study objectives or jeopardize the safety of patients.

Keywords: hypertension endothelium resveratrol clinical trials